Literature DB >> 3552069

Supplementary analysis at the conclusion of a sequential clinical trial.

J Whitehead.   

Abstract

Suppose that a clinical trial has been carried out using a sequential design. Any analysis that neglects the monitoring of the trial is potentially biased, and this holds for analyses of responses not directly used to determine whether the study should be stopped. Although valid methods exist to deal with the responses actually used in the sequential design, little has been written about secondary analyses of further responses. In this paper, two approaches to secondary analyses are explored. One is a conditional approach that avoids the problems of bias, the other an unconditional approach that allows for the sequential nature of the trial. The two methods are illustrated by application to three examples, each concerning a different type of response variable.

Mesh:

Year:  1986        PMID: 3552069

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

1.  Survivor function estimators under group sequential monitoring based on the logrank statistic.

Authors:  Malka Gorfine
Journal:  Lifetime Data Anal       Date:  2003-06       Impact factor: 1.588

2.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

3.  Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.

Authors:  Laura Flight; Steven Julious; Alan Brennan; Susan Todd
Journal:  Med Decis Making       Date:  2021-12-03       Impact factor: 2.583

4.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.